Background: One of the limiting factors in adherence to GH therapy, is satisfaction with the administration device used.
Objective and hypotheses: With the emergence of a new biosmiliar GH (BGH) administration device, we will assess the simplicity, ease of use, management and pain perceived by the patients.
Method: Prospective through survey caregivers and children treated with BGH at least for 6 months. Signed informed consent was required. The questionnaire consists of 13 questions analysing four components: preparation, fixing of the dose, injection of the medication and maintenance. The perception of pain was measured by visual analogue scale expressed in numerical score.
Results: 23 patients/caregivers were interviewed; The dose average receiving was 0.78 mg/day. 60.8% were female. three patients did not complete the second questionnaire. 33.3% of the patients increased their participation in the self-administration of medication 89.5% of the patients prefer the new device and 10.5% the old device. On the pain scale, the average score for the old device was 2.1 (maximum: 6; minimum: 0); in 75% of patients, the score was <2. With the new device the average scale was 1.7 and 80% of patients scored < 2 (P: ns)
|Old device n=23||New device n=20||P|
|General scale||Very easy 56.5%||Very easy 70%||ns|
|Preparation (three questions)||Very easy 55.1%||Very easy 73.3%||< 0.05|
|Fixing dose (three questions)||Very easy 63.8%||Very easy 70%||ns|
|Injection (four questions)||Very easy 46.7%||Very easy 66.25%||< 0.05|
|Maintenance (two questions)||Very easy 69.6%||Very easy 87.5%||ns|
Conclusion: The new device analysed has good acceptance among patients. Preparation and injection is easier with the new device. One of the most important effects is the increase in self-administration.
01 - 03 Oct 2015
European Society for Paediatric Endocrinology